Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6906)
All Articles published online
|
Publishing Process of This Article
|
Sep 14, 2018 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118 [PMID: 30254966 DOI: 10.5306/wjco.v9.i5.110] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v9/i5/110.htm |
| Number | Citing Articles |
| 1 |
Tomas Buchler, Igor Kiss, Jana Hornova, Ondrej Fiala, Marketa Wiesnerova, Michal Svoboda, Jiri Silar, Katerina Kopeckova, Alexandr Poprach, Jindrich Finek, Lubos Petruzelka, Bohuslav Melichar. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology 2020; 15(2): 193 doi: 10.1007/s11523-020-00705-1
|
| 2 |
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyayeva, L. V. Bolotina, F. V. Moiseyenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseyenko, A. A. Meshcheryakov, E. V. Artamonova, I. A. Pokatayev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musayeva, O. Yu. Novikova, I. Yu. Stradayeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, Ye. S. Kuzmina, Ye. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoyeva, A. I. Katz, R. R. Malina, A. A. Tryakin, S. A. Tyulyandin. Toxicity and efficacy of FOLFIRI regimen and aflibercept combination in metastatic colorectal cancer: first results of a Russian multicenter retrospective study. Malignant tumours 2019; 9(2): 53 doi: 10.18027/2224-5057-0-0-0-
|
| 3 |
Jwala Sivaccumar, Annamaria Sandomenico, Luigi Vitagliano, Menotti Ruvo. Monoclonal Antibodies: A Prospective and Retrospective View. Current Medicinal Chemistry 2021; 28(3): 435 doi: 10.2174/0929867327666200219142231
|
| 4 |
Lucie Heczko, Václav Liška, Ondřej Vyčítal, Ondřej Fiala, Simona Šůsová, Viktor Hlaváč, Pavel Souček. Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance. Human Genomics 2024; 18(1) doi: 10.1186/s40246-024-00644-2
|
| 5 |
Xiaojun Liang, Jie Shen. Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis. Journal of Chemotherapy 2020; 32(1): 41 doi: 10.1080/1120009X.2019.1692282
|
| 6 |
Hélène Bellio, Aurélie Bertaut, Alice Hervieu, Sylvie Zanetta, Audrey Hennequin, Julie Vincent, Rémi Palmier, Leila Bengrine-Lefevre, François Ghiringhelli, Jean-David Fumet. Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers 2021; 13(21): 5472 doi: 10.3390/cancers13215472
|
| 7 |
Madeline Devaux, Laura Gerard, Corentin Richard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt, François Ghiringhelli. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World Journal of Clinical Oncology 2019; 10(2): 75-85 doi: 10.5306/wjco.v10.i2.75
|
| 8 |
Kei Muro, Taylor Salinardi, Arvind Rup Singh, Teresa Macarulla. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers 2020; 12(4): 844 doi: 10.3390/cancers12040844
|
| 9 |
Eleonora Lai, Stefano Cascinu, Mario Scartozzi. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.637823
|
| 10 |
David K. Lau, Justin Mencel, Ian Chau. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opinion on Drug Safety 2022; 21(5): 589 doi: 10.1080/14740338.2022.2008905
|